Skip to main content
PMC home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1994 Jun 25;22(12):2274–2281. doi: 10.1093/nar/22.12.2274

Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage.

M Bigioni 1, F Zunino 1, G Capranico 1
PMCID: PMC523684  PMID: 8036155

Abstract

Antitumor drugs, such as anthracyclines, interfere with mammalian DNA topoisomerase II by forming a ternary complex, DNA-drug-enzyme, in which DNA strands are cleaved and covalently linked to the enzyme. In this work, a synthetic 36-bp DNA oligomer derived from SV40 and mutated variants were used to determine the effects of base mutations on DNA cleavage levels produced by murine topoisomerase II with and without idarubicin. Although site competition could affect cleavage levels, mutation effects were rather similar among several cleavage sites. The major sequence determinants of topoisomerase II DNA cleavage without drugs are up to five base pairs apart from the strand cut, suggesting that DNA protein contacts involving these bases are particularly critical for DNA site recognition. Cleavage sites with adenines at positions -1 were detected without idarubicin only under conditions favouring enzyme binding to DNA, showing that these sites are low affinity sites for topoisomerase II DNA cleavage and/or binding. Moreover, the results indicated that the sequence 5'-(A)TA/(A)-3' (the slash indicates the cleaved bond, parenthesis indicate conditioned preference) from -3 to +1 positions constitutes the complete base sequence preferred by anthracyclines. An important finding was that mutations that improve the fit to the above consensus on one strand can also increase cleavage on the opposite strand, suggesting that a drug molecule may effectively interact with one enzyme subunit only and trap the whole dimeric enzyme. These findings documented that DNA recognition by topoisomerase II may occur at one or the other strand, and not necessarily at both of them, and that the two subunits can act cooperatively to cleave a double helix.

Full text

PDF
2280

Images in this article

2275Image
on p.2275
2276Image
on p.2276
2277Image
on p.2277
2277Image
on p.2277
2279Image
on p.2279

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi Y., Luke M., Laemmli U. K. Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell. 1991 Jan 11;64(1):137–148. doi: 10.1016/0092-8674(91)90215-k. [DOI] [PubMed] [Google Scholar]
  2. Berrios M., Osheroff N., Fisher P. A. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4142–4146. doi: 10.1073/pnas.82.12.4142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Capranico G., De Isabella P., Tinelli S., Bigioni M., Zunino F. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry. 1993 Mar 30;32(12):3038–3046. doi: 10.1021/bi00063a015. [DOI] [PubMed] [Google Scholar]
  4. Capranico G., Kohn K. W., Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 1990 Nov 25;18(22):6611–6619. doi: 10.1093/nar/18.22.6611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Capranico G., Palumbo M., Tinelli S., Mabilia M., Pozzan A., Zunino F. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J Mol Biol. 1994 Jan 28;235(4):1218–1230. doi: 10.1006/jmbi.1994.1075. [DOI] [PubMed] [Google Scholar]
  6. Capranico G., Tinelli S., Zunino F., Kohn K. W., Pommier Y. Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers. Biochemistry. 1993 Jan 12;32(1):145–152. doi: 10.1021/bi00052a020. [DOI] [PubMed] [Google Scholar]
  7. Capranico G., Zunino F. DNA topoisomerase-trapping antitumour drugs. Eur J Cancer. 1992;28A(12):2055–2060. doi: 10.1016/0959-8049(92)90255-z. [DOI] [PubMed] [Google Scholar]
  8. Capranico G., Zunino F., Kohn K. W., Pommier Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry. 1990 Jan 16;29(2):562–569. doi: 10.1021/bi00454a033. [DOI] [PubMed] [Google Scholar]
  9. Chaires J. B., Fox K. R., Herrera J. E., Britt M., Waring M. J. Site and sequence specificity of the daunomycin-DNA interaction. Biochemistry. 1987 Dec 15;26(25):8227–8236. doi: 10.1021/bi00399a031. [DOI] [PubMed] [Google Scholar]
  10. Chan V. T., Ng S. W., Eder J. P., Schnipper L. E. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J Biol Chem. 1993 Jan 25;268(3):2160–2165. [PubMed] [Google Scholar]
  11. De Isabella P., Capranico G., Binaschi M., Tinelli S., Zunino F. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. Mol Pharmacol. 1990 Jan;37(1):11–16. [PubMed] [Google Scholar]
  12. Downes C. S., Mullinger A. M., Johnson R. T. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8895–8899. doi: 10.1073/pnas.88.20.8895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Earnshaw W. C., Halligan B., Cooke C. A., Heck M. M., Liu L. F. Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol. 1985 May;100(5):1706–1715. doi: 10.1083/jcb.100.5.1706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fisher L. M., Barot H. A., Cullen M. E. DNA gyrase complex with DNA: determinants for site-specific DNA breakage. EMBO J. 1986 Jun;5(6):1411–1418. doi: 10.1002/j.1460-2075.1986.tb04375.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fisher L. M., Mizuuchi K., O'Dea M. H., Ohmori H., Gellert M. Site-specific interaction of DNA gyrase with DNA. Proc Natl Acad Sci U S A. 1981 Jul;78(7):4165–4169. doi: 10.1073/pnas.78.7.4165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fossé P., René B., Le Bret M., Paoletti C., Saucier J. M. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res. 1991 Jun 11;19(11):2861–2868. doi: 10.1093/nar/19.11.2861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Freudenreich C. H., Kreuzer K. N. Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors. EMBO J. 1993 May;12(5):2085–2097. doi: 10.1002/j.1460-2075.1993.tb05857.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gasser S. M., Laroche T., Falquet J., Boy de la Tour E., Laemmli U. K. Metaphase chromosome structure. Involvement of topoisomerase II. J Mol Biol. 1986 Apr 20;188(4):613–629. doi: 10.1016/s0022-2836(86)80010-9. [DOI] [PubMed] [Google Scholar]
  19. Holm C., Goto T., Wang J. C., Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell. 1985 Jun;41(2):553–563. doi: 10.1016/s0092-8674(85)80028-3. [DOI] [PubMed] [Google Scholar]
  20. Holm C., Stearns T., Botstein D. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol Cell Biol. 1989 Jan;9(1):159–168. doi: 10.1128/mcb.9.1.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Huff A. C., Kreuzer K. N. Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases. J Biol Chem. 1990 Nov 25;265(33):20496–20505. [PubMed] [Google Scholar]
  22. Lee M. P., Sander M., Hsieh T. Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites. J Biol Chem. 1989 Dec 25;264(36):21779–21787. [PubMed] [Google Scholar]
  23. Lindsley J. E., Wang J. C. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J Biol Chem. 1993 Apr 15;268(11):8096–8104. [PubMed] [Google Scholar]
  24. Lindsley J. E., Wang J. C. Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP binding. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10485–10489. doi: 10.1073/pnas.88.23.10485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lindsley J. E., Wang J. C. Study of allosteric communication between protomers by immunotagging. Nature. 1993 Feb 25;361(6414):749–750. doi: 10.1038/361749a0. [DOI] [PubMed] [Google Scholar]
  26. Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.002031. [DOI] [PubMed] [Google Scholar]
  27. Liu L. F., Wang J. C. Supercoiling of the DNA template during transcription. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7024–7027. doi: 10.1073/pnas.84.20.7024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Minford J., Pommier Y., Filipski J., Kohn K. W., Kerrigan D., Mattern M., Michaels S., Schwartz R., Zwelling L. A. Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry. 1986 Jan 14;25(1):9–16. doi: 10.1021/bi00349a002. [DOI] [PubMed] [Google Scholar]
  29. Morrison A., Cozzarelli N. R. Site-specific cleavage of DNA by E. coli DNA gyrase. Cell. 1979 May;17(1):175–184. doi: 10.1016/0092-8674(79)90305-2. [DOI] [PubMed] [Google Scholar]
  30. Phillips D. R., White R. J., Trist H., Cullinane C., Dean D., Crothers D. M. New insight into drug-DNA interactions at individual drug binding sites probed by RNA polymerase during active transcription of the DNA. Anticancer Drug Des. 1990 Feb;5(1):21–29. [PubMed] [Google Scholar]
  31. Pommier Y., Capranico G., Orr A., Kohn K. W. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res. 1991 Nov 11;19(21):5973–5980. doi: 10.1093/nar/19.21.5973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pullman B. Sequence specificity in the binding of anti-tumour anthracyclines to DNA: a success of theory. Anticancer Drug Des. 1991 May;6(2):95–105. [PubMed] [Google Scholar]
  33. Quigley G. J., Wang A. H., Ughetto G., van der Marel G., van Boom J. H., Rich A. Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG). Proc Natl Acad Sci U S A. 1980 Dec;77(12):7204–7208. doi: 10.1073/pnas.77.12.7204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Roca J., Wang J. C. The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell. 1992 Nov 27;71(5):833–840. doi: 10.1016/0092-8674(92)90558-t. [DOI] [PubMed] [Google Scholar]
  35. Sander M., Hsieh T. S. Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site. Nucleic Acids Res. 1985 Feb 25;13(4):1057–1072. doi: 10.1093/nar/13.4.1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Shen L. L., Kohlbrenner W. E., Weigl D., Baranowski J. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J Biol Chem. 1989 Feb 15;264(5):2973–2978. [PubMed] [Google Scholar]
  37. Spitzner J. R., Muller M. T. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res. 1988 Jun 24;16(12):5533–5556. doi: 10.1093/nar/16.12.5533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sullivan D. M., Latham M. D., Rowe T. C., Ross W. E. Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry. 1989 Jun 27;28(13):5680–5687. doi: 10.1021/bi00439a051. [DOI] [PubMed] [Google Scholar]
  39. Tapper D. P., Clayton D. A. Altered mobility of polydeoxyribonucleotides in high resolution polyacrylamide gels due to removal of terminal phosphates. Nucleic Acids Res. 1981 Dec 21;9(24):6787–6794. doi: 10.1093/nar/9.24.6787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Uemura T., Ohkura H., Adachi Y., Morino K., Shiozaki K., Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell. 1987 Sep 11;50(6):917–925. doi: 10.1016/0092-8674(87)90518-6. [DOI] [PubMed] [Google Scholar]
  41. Wang A. H., Ughetto G., Quigley G. J., Rich A. Interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 1.2-A resolution. Biochemistry. 1987 Feb 24;26(4):1152–1163. doi: 10.1021/bi00378a025. [DOI] [PubMed] [Google Scholar]
  42. Wang J. C. DNA topoisomerases. Annu Rev Biochem. 1985;54:665–697. doi: 10.1146/annurev.bi.54.070185.003313. [DOI] [PubMed] [Google Scholar]
  43. Zunino F., Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des. 1990 Nov;5(4):307–317. [PubMed] [Google Scholar]
  44. Zwelling L. A. DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metastasis Rev. 1985;4(4):263–276. doi: 10.1007/BF00048092. [DOI] [PubMed] [Google Scholar]
  45. Zwelling L. A., Hinds M., Chan D., Mayes J., Sie K. L., Parker E., Silberman L., Radcliffe A., Beran M., Blick M. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem. 1989 Oct 5;264(28):16411–16420. [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES